Oral Supplementation with Ultramicronized Palmitoylethanolamide for Joint Disease and Lameness Management in Four Jumping Horses: A Case Report.
Authors: Gugliandolo Enrico, Barbagallo Alfio, Peritore Alessio Filippo, Cuzzocrea Salvatore, Crupi Rosalia
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Four show-jumping horses presenting with treatment-refractory lameness—comprising navicular syndrome (two cases with one being chronic and complicated), distal interphalangeal joint arthrosis, and distal intertarsal joint arthritis—were supplemented orally with ultramicronized palmitoylethanolamide (PEA-um) as an adjunctive management strategy following standard diagnostic protocols including radiography, flexion testing and diagnostic anesthesia. Palmitoylethanolamide is an endogenous lipid mediator with established anti-inflammatory and analgesic properties in human and small animal medicine, though this represents the first documented application in equine practice. After four months of daily PEA-um supplementation integrated into normal feed, all four horses demonstrated complete lameness remission sufficiently robust to permit return to competitive jumping without relapse during the observation period. Whilst the case series is necessarily small, the consistent response across diverse joint pathologies suggests PEA-um warrants formal investigation in a larger, controlled trial as a potential nutraceutical adjunct for degenerative joint disease in performance horses, particularly where conventional anti-inflammatory protocols have proved inadequate. The findings merit consideration in your clinical decision-making for chronically lame horses, though controlled research data remain essential before widespread recommendation.
Read the full abstract on PubMed
Practical Takeaways
- •PEA-um supplementation may offer a non-pharmacological option for managing chronic joint disease and lameness in performance horses, particularly those unresponsive to standard treatments
- •Consider adding ultramicronized PEA to the management protocol for navicular syndrome and distal intertarsal arthritis; treatment duration of 4 months was required to observe clinical improvement
- •This small case series suggests potential benefit but controlled trials in larger horse populations are needed before making firm clinical recommendations
Key Findings
- •All four horses with non-responsive lameness showed remission of clinical signs after 4 months of daily ultramicronized palmitoylethanolamide (PEA-um) supplementation
- •Treated horses were successfully reintroduced to show jumping competition without disease recurrence following PEA-um treatment
- •This is the first reported use of PEA-um in equine medicine for joint disease management
- •PEA-um demonstrated efficacy as a nutraceutical adjunct in horses unresponsive to conventional therapies